Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Relafen Settlement Affirms Need For Tort Reform, GSK's Garnier Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Wholesalers maintain they were overcharged for Relafen while GSK patent litigation prevented generics from entering the market. GSK says wholesalers can earn higher margins on branded products.

You may also be interested in...

Tort Reform Needed To Relieve “Chronic Pain” Of Litigation, GSK Says

Legal costs within the pharmaceutical industry are becoming a "chronic pain" that can only be addressed through comprehensive tort reform, GlaxoSmithKline CEO J.P. Garnier said July 27.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts